Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert, J O'Neill… - The Lancet …, 2017 - thelancet.com
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
[引用][C] Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert, J O'Neill… - The Lancet …, 2017 - cir.nii.ac.jp
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised,
placebo-controlled pilot trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
placebo-controlled pilot trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert, J O'Neill… - The Lancet …, 2017 - Elsevier
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert… - The Lancet …, 2017 - mayoclinic.elsevierpure.com
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert, J O'Neill, H Kadouh… - 2017 - pubmed.ncbi.nlm.nih.gov
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
H Halawi, D Khemani, D Eckert, J O'Neill… - The lancet …, 2017 - europepmc.org
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
H Halawi, D Khemani, D Eckert, J O'Neill… - The Lancet …, 2017 - thelancet.com
Background Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …
obesity; however, the mechanisms of action of liraglutide are incompletely understood. We …